Tao Bai

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 6

Top Topics

Ejection Fraction

Patient Reported

Renal Cell Carcinoma

Replacement Therapy

Top Venues

British journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Haibo Wang, Lijie Zhang, Hua Liu, Yumeng Yang, Wenxiu Lu, Xuedi Cao, Xiaomei Yang, Qiong Qin, Ran Song, Duiping Feng, Songlin Wang, Tao Bai, Junqi He
PDZK1 confers sensitivity to sunitinib in clear cell renal cell carcinoma by suppressing the PDGFR-β pathway. British journal of cancer (2024)
Haibo Wang, Lijie Zhang, Hua Liu, Yumeng Yang, Wenxiu Lu, Xuedi Cao, Xiaomei Yang, Qiong Qin, Ran Song, Duiping Feng, Songlin Wang, Tao Bai, Junqi He
PDZK1 confers sensitivity to sunitinib in clear cell renal cell carcinoma by suppressing the PDGFR-β pathway. British journal of cancer 131 (2) (2024)
Haibo Wang, Lijie Zhang, Hua Liu, Yumeng Yang, Wenxiu Lu, Xuedi Cao, Xiaomei Yang, Qiong Qin, Ran Song, Duiping Feng, Songlin Wang, Tao Bai, Junqi He
PDZK1 confers sensitivity to sunitinib in clear cell renal cell carcinoma by suppressing the PDGFR-β pathway. British journal of cancer 131 (2) (2024)
Haibo Wang, Lijie Zhang, Hua Liu, Yumeng Yang, Wenxiu Lu, Xuedi Cao, Xiaomei Yang, Qiong Qin, Ran Song, Duiping Feng, Songlin Wang, Tao Bai, Junqi He
PDZK1 confers sensitivity to sunitinib in clear cell renal cell carcinoma by suppressing the PDGFR-β pathway. British journal of cancer 131 (2) (2024)
Haibo Wang, Lijie Zhang, Hua Liu, Yumeng Yang, Wenxiu Lu, Xuedi Cao, Xiaomei Yang, Qiong Qin, Ran Song, Duiping Feng, Songlin Wang, Tao Bai, Junqi He
PDZK1 confers sensitivity to sunitinib in clear cell renal cell carcinoma by suppressing the PDGFR-β pathway. British journal of cancer 131 (2) (2024)
Haibo Wang, Lijie Zhang, Hua Liu, Yumeng Yang, Wenxiu Lu, Xuedi Cao, Xiaomei Yang, Qiong Qin, Ran Song, Duiping Feng, Songlin Wang, Tao Bai, Junqi He
PDZK1 confers sensitivity to sunitinib in clear cell renal cell carcinoma by suppressing the PDGFR-β pathway. British journal of cancer 131 (2) (2024)